|
Mean (SD), range |
|
|
Age in years |
32.7 (12.6), 19-71 |
14.2
(1.6), 12-17 |
|
Gender, % female |
66% |
70% |
|
Genetic mutation (n %) |
|
|
|
F508del/F508del |
21 (51.2) |
10 (100) |
|
F508del/other |
13 (31.7) |
|
|
Other |
7 (17.1) |
|
|
Use of CFTR-modulator(s) (n %) |
28 (68.3) |
9 (90) |
|
Symkevi |
2 (4.9) |
|
|
Orkambi |
1 (2.4) |
|
|
Kaftrio/Trikafta |
22 (53.7) |
8 (80) |
|
Kalydeco |
1 (2.4) |
|
|
Combination of Kaftrio/Trikafta & Kalydeco |
2 (2.4) |
1 (10) |
|
No |
13 (31.7) |
1 (10) |
|
Pancreatic function (n %) |
|
|
|
Sufficient |
6 (14.6) |
1 (10) |
|
Insufficient, Endocrine |
4 (9.8) |
|
|
Insufficient, Exocrine |
16 (39) |
9 (90) |
|
Insufficient, Both endocrine and exocrine |
15 (36.6) |
|
|
Mean FEV1 in % of predicted (SD) |
72.1 (23.8) |
83.6 (15.90) |
|
BMI |
22.2 (2.6), 18.6-28.4 |
20.2 (2.2),
17.1-24.4 |
|
Highest level of education |
N (%) |
|
|
Low/Middle/High1 |
9 (23)/21 (54)/9 (23) |
1 10 (100) |
|
Average working hours per weekᶲ |
N (%) |
|
|
|
0 |
17 (42) |
NA |
|
1-12 |
6 (15) |
NA |
|
13-24 |
7 (17) |
NA |
|
> 25 |
9 (22) |
NA |
|
Unknown |
2 (5) |
NA |
Relational status ᶲ |
|
|
|
|
Single |
21 (51) |
NA |
|
Married |
10 (24) |
NA |
|
Living together with partner |
10 (24) |
NA |
Use of medication other than CF medication |
|
|
|
|
Yes |
14 (34) |
2 (20) |
|
No |
27 (66) |
8 (80) |
Sport |
N (%) |
|
|
|
Yes |
30 (76) |
7 (70) |
|
No |
10 (24) |
3 (30) |
|
Unknown |
1 (2) |
|
Probiotic |
N (%) |
|
|
|
Yes |
11 (27) |
0 (0) |
|
No |
30 (73) |
10 (100) |